{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:04Z","timestamp":1791316204093,"version":"4.3.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG, Research Training Group 2254, project B03"],"award-info":[{"award-number":["DFG, Research Training Group 2254, project B03"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["Research Group Linkage Programme"],"award-info":[{"award-number":["Research Group Linkage Programme"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["Research Group Linkage Programme"],"award-info":[{"award-number":["Research Group Linkage Programme"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"],"award-info":[{"award-number":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"],"award-info":[{"award-number":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"],"award-info":[{"award-number":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"],"award-info":[{"award-number":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"],"award-info":[{"award-number":["Priority Program \u2018Translational Oncology\u2019, project `CTChigh\u00b4, 70114705"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer with limited treatment options and a propensity towards chemoresistance. Given the lack of targetable receptors, treatment relies primarily on chemotherapy. While mechanisms leading to chemoresistance are vastly unknown, DNA damage tolerance (DDT) pathways have emerged as potential drivers of chemoresistance. Herein, we report a phenotypic characterization of four TNBC- and six non-TNBC cell lines, which supports the relevance of DDT in the TNBC response to chemotherapy. We unveiled an association between DDT pathway activation through PCNA-ubiquitination, augmented epithelial-to-mesenchymal transition (EMT) and stemness features, specifically in 3D spheroid culture from TNBC cells. Analysis of replication dynamics revealed a pronounced replication slowdown in 3D- versus 2D-cultured TNBC but not in non-TNBC cells. The exploration of DDT pathway usage in three TNBC cell lines (MDA-MB-231, Hs578t, MDA-MB-468) uncovers reliance on ZRANB3-, HLTF- and SMARCAL1-dependent fork reversal in 3D, while translesion DNA synthesis (TLS) polymerases (POLs) were more active under 2D conditions. Screening cytotoxicity with a panel of ten drugs targeting key DDT pathway components identified POL\u03b6 inhibition (JH-RE-06; IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009\u2264\u20097\u2009\u00b5M\/48\u2009h) and CHK1 inhibition (PF477736; IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009\u2264\u200920\u2009\u00b5M\/48\u2009h) as the most potent single-agent treatments in all three cell lines under both conditions. Mechanistically, both POL\u03b6 and CHK1 inhibition target several DDT pathways, in sum, causing replication slowdown, revealed consistently for CHK1. While TNBC cell lines were largely unresponsive to Olaparib mono-treatment, especially in 3D culture, all three cell lines were resensitized by combining Olaparib with low-dose POL\u03b6-, CHK1-, or RAD51 inhibitor, except for 3D-cultured MDA-MB-231 cells, which may resist Olaparib due to their high ZRANB3 complex formation in the nucleus. These findings identify key DDT pathway components such as POL\u03b6 and CHK1 as druggable targets that alone or in combination with Olaparib may overcome chemoresistance in TNBC.\n                  <\/jats:p>","DOI":"10.1038\/s41420-026-03377-4","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:54:15Z","timestamp":1791305655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting common denominators of DNA damage tolerance mechanisms as therapeutic strategy to cope with dynamic phenotypic changes in triple-negative breast cancer cells"],"prefix":"10.1038","volume":"12","author":[{"given":"Kathrin","family":"Niedermayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Oechsle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-2772","authenticated-orcid":false,"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-8067","authenticated-orcid":false,"given":"Thomas W. P.","family":"Friedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Rack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Gottifredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2397-5041","authenticated-orcid":false,"given":"Lisa","family":"Wiesm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3377_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02111-9","volume":"40","author":"H Swaminathan","year":"2023","unstructured":"Swaminathan H, Saravanamurali K, Yadav SA. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment. Med Oncol. 2023;40:238.","journal-title":"Med Oncol"},{"key":"3377_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31:1154\u201362.","journal-title":"Nat Med"},{"key":"3377_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/cancers17020228","volume":"17","author":"E B\u0142aszczak","year":"2025","unstructured":"B\u0142aszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A. Triple-negative breast cancer progression and drug resistance in the context of epithelial\u2013mesenchymal transition. Cancers (Basel). 2025;17:228.","journal-title":"Cancers (Basel)"},{"key":"3377_CR4","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/cncr.23930","volume":"113","author":"NU Lin","year":"2008","unstructured":"Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer. 2008;113:2638\u201345.","journal-title":"Cancer"},{"key":"3377_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61.","journal-title":"Breast Cancer Res"},{"key":"3377_CR6","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/ijms23031665","volume":"23","author":"P Ferrari","year":"2022","unstructured":"Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci. 2022;23:1665.","journal-title":"Int J Mol Sci"},{"key":"3377_CR7","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.3390\/molecules27154736","volume":"27","author":"JA Nickoloff","year":"2022","unstructured":"Nickoloff JA. Targeting replication stress response pathways to enhance genotoxic chemo- and radiotherapy. Molecules. 2022;27:4736.","journal-title":"Molecules"},{"key":"3377_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/OTT.S499226","volume":"ume 18","author":"M Muzzana","year":"2025","unstructured":"Muzzana M, Broggini M, Damia G. The landscape of PARP inhibitors in solid cancers. Onco Targets Ther. 2025;ume 18:297\u2013317.","journal-title":"Onco Targets Ther"},{"key":"3377_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41580-020-0257-5","volume":"21","author":"M Berti","year":"2020","unstructured":"Berti M, Cortez D, Lopes M. The plasticity of DNA replication forks in response to clinically relevant genotoxic stress. Nat Rev Mol Cell Biol. 2020;21:633\u201351.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3377_CR10","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/cells12081169","volume":"12","author":"M Thomas","year":"2023","unstructured":"Thomas M, Dubacq C, Rabut E, Lopez BS, Guirouilh-Barbat J. Noncanonical roles of RAD51. Cells. 2023;12:1169.","journal-title":"Cells"},{"key":"3377_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrm3289","volume":"13","author":"JE Sale","year":"2012","unstructured":"Sale JE, Lehmann AR, Woodgate R, Y-family DNA. polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol. 2012;13:141\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3377_CR12","doi-asserted-by":"publisher","first-page":"E4311","DOI":"10.1073\/pnas.1605828113","volume":"113","author":"S Hampp","year":"2016","unstructured":"Hampp S, Kiessling T, Buechle K, Mansilla SF, Thomale J, Rall M, et al. DNA damage tolerance pathway involving DNA polymerase \u03b9 and the tumor suppressor p53 regulates DNA replication fork progression. Proc Natl Acad Sci USA. 2016;113:E4311\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3377_CR13","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.1093\/nar\/gkab526","volume":"49","author":"M Ihle","year":"2021","unstructured":"Ihle M, Biber S, Schroeder IS, Blattner C, Deniz M, Damia G, et al. Impact of the interplay between stemness features, p53 and pol iota on replication pathway choices. Nucleic Acids Res. 2021;49:7457\u201375.","journal-title":"Nucleic Acids Res"},{"key":"3377_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06783-7","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo Y, Wu H, Wiesm\u00fcller L, Chen M. Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance. Cell Death Dis. 2024;15:412.","journal-title":"Cell Death Dis"},{"key":"3377_CR15","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1093\/nar\/gkae061","volume":"52","author":"BA Casta\u00f1o","year":"2024","unstructured":"Casta\u00f1o BA, Schorer S, Guo Y, Calzetta NL, Gottifredi V, Wiesm\u00fcller L, et al. The levels of p53 govern the hierarchy of DNA damage tolerance pathway usage. Nucleic Acids Res. 2024;52:3740\u201360.","journal-title":"Nucleic Acids Res"},{"key":"3377_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.molcel.2014.12.038","volume":"57","author":"M Fumasoni","year":"2015","unstructured":"Fumasoni M, Zwicky K, Vanoli F, Lopes M, Branzei D, Error-Free DNA. Damage tolerance and sister chromatid proximity during DNA replication rely on the Pol\u03b1\/Primase\/Ctf4 complex. Mol Cell. 2015;57:812\u201323.","journal-title":"Mol Cell"},{"key":"3377_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.molcel.2019.10.008","volume":"77","author":"A Quinet","year":"2020","unstructured":"Quinet A, Tirman S, Jackson J, \u0160vikovi\u0107 S, Lema\u00e7on D, Carvajal-Maldonado D, et al. PRIMPOL-mediated adaptive response suppresses replication fork reversal in BRCA-deficient cells. Mol Cell. 2020;77:461\u201374.","journal-title":"Mol Cell"},{"key":"3377_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19570-7","volume":"11","author":"AL Piberger","year":"2020","unstructured":"Piberger AL, Bowry A, Kelly RDW, Walker AK, Gonz\u00e1lez-Acosta D, Bailey LJ, et al. PrimPol-dependent single-stranded gap formation mediates homologous recombination at bulky DNA adducts. Nat Commun. 2020;11:5863.","journal-title":"Nat Commun"},{"key":"3377_CR19","doi-asserted-by":"publisher","first-page":"7696","DOI":"10.1128\/MCB.01076-06","volume":"26","author":"T Ohkumo","year":"2006","unstructured":"Ohkumo T, Kondo Y, Yokoi M, Tsukamoto T, Yamada A, Sugimoto T, et al. UV-B radiation induces epithelial tumors in mice lacking DNA polymerase \u03b7 and mesenchymal tumors in mice deficient for DNA polymerase \u03b9. Mol Cell Biol. 2006;26:7696\u2013706.","journal-title":"Mol Cell Biol"},{"key":"3377_CR20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/cancers14040997","volume":"14","author":"B Heitmeir","year":"2022","unstructured":"Heitmeir B, Deniz M, Janni W, Rack B, Schochter F, Wiesm\u00fcller L. Circulating tumor cells in breast cancer patients: a balancing act between stemness, EMT features and DNA damage responses. Cancers (Basel). 2022;14:997.","journal-title":"Cancers (Basel)"},{"key":"3377_CR21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.molcel.2020.04.031","volume":"78","author":"G Bai","year":"2020","unstructured":"Bai G, Kermi C, Stoy H, Schiltz CJ, Bacal J, Zaino AM, et al. HLTF promotes fork reversal, limiting replication stress resistance and preventing multiple mechanisms of unrestrained DNA synthesis. Mol Cell. 2020;78:1237\u201351.","journal-title":"Mol Cell"},{"key":"3377_CR22","doi-asserted-by":"publisher","unstructured":"Nayak S, Calvo JA, Cong K, Peng M, Berthiaume E, Jackson J, et al. Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability. Sci Adv 2020;6. https:\/\/doi.org\/10.1126\/sciadv.aaz7808.","DOI":"10.1126\/sciadv.aaz7808"},{"key":"3377_CR23","doi-asserted-by":"publisher","unstructured":"Malka MM, Eberle J, Niedermayer K, Zlotos DP, Wiesm\u00fcller L. Dual parp and rad51 inhibitory drug conjugates show synergistic and selective effects on breast cancer cells. Biomolecules 2021;11. https:\/\/doi.org\/10.3390\/biom11070981.","DOI":"10.3390\/biom11070981"},{"key":"3377_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/biom12020248","volume":"12","author":"A D\u00edaz-Talavera","year":"2022","unstructured":"D\u00edaz-Talavera A, Montero-Conde C, Leandro-Garc\u00eda L, Robledo M. PrimPol: a breakthrough among DNA replication enzymes and a potential new target for cancer therapy. Biomolecules. 2022;12:248.","journal-title":"Biomolecules"},{"key":"3377_CR25","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.1021\/acs.jmedchem.6b00596","volume":"59","author":"DM Korzhnev","year":"2016","unstructured":"Korzhnev DM, Hadden MK. Targeting the translesion synthesis pathway for the development of anti-cancer chemotherapeutics. J Med Chem. 2016;59:9321\u201336.","journal-title":"J Med Chem"},{"key":"3377_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cell.2019.05.028","volume":"178","author":"JL Wojtaszek","year":"2019","unstructured":"Wojtaszek JL, Chatterjee N, Najeeb J, Ramos A, Lee M, Bian K, et al. A small molecule targeting mutagenic translesion synthesis improves chemotherapy. Cell. 2019;178:152\u20139.e11.","journal-title":"Cell"},{"key":"3377_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13543784.2021.1850692","volume":"30","author":"SM Patel","year":"2021","unstructured":"Patel SM, Dash RC, Hadden MK. Translesion synthesis inhibitors as a new class of cancer chemotherapeutics. Expert Opin Investig Drugs. 2021;30:13\u201324.","journal-title":"Expert Opin Investig Drugs"},{"key":"3377_CR28","doi-asserted-by":"publisher","first-page":"e1006842","DOI":"10.1371\/journal.pgen.1006842","volume":"13","author":"K Yamanaka","year":"2017","unstructured":"Yamanaka K, Chatterjee N, Hemann MT, Walker GC. Inhibition of mutagenic translesion synthesis: a possible strategy for improving chemotherapy?. PLoS Genet. 2017;13:e1006842.","journal-title":"PLoS Genet"},{"key":"3377_CR29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao M-J, Eaton ENG, Ayyan A, Zhou AY, et al. The epithelial\u2013mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704\u201315.","journal-title":"Cell"},{"key":"3377_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrm1835","volume":"7","author":"JP Thiery","year":"2006","unstructured":"Thiery JP, Sleeman JP. Complex networks orchestrate epithelial\u2013mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3377_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/15384101.2015.1006048","volume":"14","author":"P Zhang","year":"2015","unstructured":"Zhang P, Sun Y, Ma L. ZEB1: At the crossroads of epithelial\u2013mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015;14:481\u20137.","journal-title":"Cell Cycle"},{"key":"3377_CR32","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","volume":"68","author":"A Satelli","year":"2011","unstructured":"Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033\u201346.","journal-title":"Cell Mol Life Sci"},{"key":"3377_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.stemcr.2013.11.009","volume":"2","author":"S Liu","year":"2014","unstructured":"Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2014;2:78\u201391.","journal-title":"Stem Cell Rep"},{"key":"3377_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0408-8","volume":"16","author":"Z Zhao","year":"2014","unstructured":"Zhao Z, Lu P, Zhang H, Xu H, Gao N, Li M, et al. Nestin positively regulates the Wnt\/\u03b2-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res. 2014;16:408.","journal-title":"Breast Cancer Res"},{"key":"3377_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4161\/cbt.9.2.10583","volume":"9","author":"S-Y Sun","year":"2010","unstructured":"Sun S-Y. N-acetylcysteine, reactive oxygen species and beyond. Cancer Biol Ther. 2010;9:109\u201310.","journal-title":"Cancer Biol Ther"},{"key":"3377_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ymeth.2016.04.019","volume":"108","author":"J Nieminuszczy","year":"2016","unstructured":"Nieminuszczy J, Schwab RA, Niedzwiedz W. The DNA fibre technique\u2014tracking helicases at work. Methods. 2016;108:92\u20138.","journal-title":"Methods"},{"key":"3377_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nature00991","volume":"419","author":"C Hoege","year":"2002","unstructured":"Hoege C, Pfander B, Moldovan G-L, Pyrowolakis G, Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature. 2002;419:135\u201341.","journal-title":"Nature"},{"key":"3377_CR38","doi-asserted-by":"publisher","first-page":"8348","DOI":"10.1093\/nar\/gkz705","volume":"47","author":"SK Martin","year":"2019","unstructured":"Martin SK, Wood RD. DNA polymerase \u03b6 in DNA replication and repair. Nucleic Acids Res. 2019;47:8348\u201361.","journal-title":"Nucleic Acids Res"},{"key":"3377_CR39","doi-asserted-by":"publisher","first-page":"9027","DOI":"10.3390\/ijms21239027","volume":"21","author":"EO Boldinova","year":"2020","unstructured":"Boldinova EO, Belousova EA, Gagarinskaya DI, Maltseva EA, Khodyreva SN, Lavrik OI, et al. Strand displacement activity of PrimPol. Int J Mol Sci. 2020;21:9027.","journal-title":"Int J Mol Sci"},{"key":"3377_CR40","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1016\/j.molcel.2021.08.016","volume":"81","author":"A Taglialatela","year":"2021","unstructured":"Taglialatela A, Leuzzi G, Sannino V, Cuella-Martin R, Huang JW, Wu-Baer F, et al. REV1-Pol\u03b6 maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps. Mol Cell. 2021;81:4008\u201325.","journal-title":"Mol Cell"},{"key":"3377_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/10409238.2017.1380597","volume":"52","author":"LA Poole","year":"2017","unstructured":"Poole LA, Cortez D. Functions of SMARCAL1, ZRANB3, and HLTF in maintaining genome stability. Crit Rev Biochem Mol Biol. 2017;52:696\u2013714.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"3377_CR42","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/genes15101271","volume":"15","author":"S Bedaiwi","year":"2024","unstructured":"Bedaiwi S, Usmani A, Carty MP. Canonical and non-canonical roles of human DNA polymerase \u03b7. Genes (Basel). 2024;15:1271.","journal-title":"Genes (Basel)"},{"key":"3377_CR43","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1093\/nar\/gkw123","volume":"44","author":"B Pilzecker","year":"2016","unstructured":"Pilzecker B, Buoninfante OA, Pritchard C, Blomberg OS, Huijbers IJ, van den Berk PCM, et al. PrimPol prevents APOBEC\/AID family mediated DNA mutagenesis. Nucleic Acids Res. 2016;44:4734\u201344.","journal-title":"Nucleic Acids Res"},{"key":"3377_CR44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.yexcr.2014.07.009","volume":"329","author":"I Saugar","year":"2014","unstructured":"Saugar I, Ortiz-Baz\u00e1n M\u00c1, Tercero JA, Tolerating DNA. damage during eukaryotic chromosome replication. Exp Cell Res. 2014;329:170\u20137.","journal-title":"Exp Cell Res"},{"key":"3377_CR45","doi-asserted-by":"crossref","first-page":"11340","DOI":"10.1093\/nar\/gky013","volume":"46","author":"Y Masuda","year":"2018","unstructured":"Masuda Y, Mitsuyuki S, Kanao R, Hishiki A, Hashimoto H, Masutani C. Regulation of HLTF-mediated PCNA polyubiquitination by RFC and PCNA monoubiquitination levels determines choice of damage tolerance pathway. Nucleic Acids Res. 2018;46:11340\u201356.","journal-title":"Nucleic Acids Res"},{"key":"3377_CR46","doi-asserted-by":"publisher","first-page":"7163","DOI":"10.1093\/nar\/gkz531","volume":"47","author":"B Pilzecker","year":"2019","unstructured":"Pilzecker B, Buoninfante OA, Jacobs H. DNA damage tolerance in stem cells, ageing, mutagenesis, disease and cancer therapy. Nucleic Acids Res. 2019;47:7163\u201381.","journal-title":"Nucleic Acids Res"},{"key":"3377_CR47","doi-asserted-by":"publisher","unstructured":"Mehta KPM, Thada V, Zhao R, Krishnamoorthy A, Leser M, Lindsey Rose K et al. CHK1 phosphorylates PRIMPOL to promote replication stress tolerance. Sci Adv 2022;8. https:\/\/doi.org\/10.1126\/sciadv.abm0314.","DOI":"10.1126\/sciadv.abm0314"},{"key":"3377_CR48","doi-asserted-by":"publisher","unstructured":"Rainey MD, Quinlan A, Cazzaniga C, Mijic S, Martella O, Krietsch J et al. CDC7 kinase promotes MRE11 fork processing, modulating fork speed and chromosomal breakage. EMBO Rep 2020;21. https:\/\/doi.org\/10.15252\/embr.201948920.","DOI":"10.15252\/embr.201948920"},{"key":"3377_CR49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1055\/a-1483-2782","volume":"81","author":"M Untch","year":"2021","unstructured":"Untch M, Fasching PA, Brucker SY, Budach W, Denkert C, Haidinger R, et al. Treatment of patients with early breast cancer: evidence, controversies, consensus. Geburtshilfe Frauenheilkd. 2021;81:637\u201353.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"3377_CR50","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475\u201395.","journal-title":"Ann Oncol"},{"key":"3377_CR51","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/0006-2952(88)90656-9","volume":"37","author":"M Broggini","year":"1988","unstructured":"Broggini M, Grandi M, Ubezio P, Geroni C, Giuliani FC, D\u2019Incalci M. Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline. Biochem Pharm. 1988;37:4423\u201331.","journal-title":"Biochem Pharm"},{"key":"3377_CR52","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial\u2013mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13:100773.","journal-title":"Transl Oncol"},{"key":"3377_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2789","volume":"13","author":"CD May","year":"2011","unstructured":"May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial\u2013mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011;13:202.","journal-title":"Breast Cancer Res"},{"key":"3377_CR54","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.2147\/OTT.S91863","volume":"8","author":"Y Tang","year":"2015","unstructured":"Tang Y, Wang S, Jiang J, Liang X. Links between cancer stem cells and epithelial-mesenchymal transition. Onco Targets Ther. 2015;8:2973.","journal-title":"Onco Targets Ther"},{"key":"3377_CR55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41580-020-00292-z","volume":"21","author":"J Halliwell","year":"2020","unstructured":"Halliwell J, Barbaric I, Andrews PW. Acquired genetic changes in human pluripotent stem cells: origins and consequences. Nat Rev Mol Cell Biol. 2020;21:715\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2988\u20133007","key":"3377_CR56","first-page":"e20","volume":"185","author":"KL Palmerola","year":"2022","unstructured":"Palmerola KL, Amrane S, De Los Angeles A, Xu S, Wang N, de Pinho J, et al. Replication stress impairs chromosome segregation and preimplantation development in human embryos. Cell. 2022;185(2988\u20133007):e20.","journal-title":"Cell"},{"key":"3377_CR57","doi-asserted-by":"publisher","first-page":"12188","DOI":"10.1093\/nar\/gkaa974","volume":"48","author":"S Biber","year":"2020","unstructured":"Biber S, Pospiech H, Gottifredi V, Wiesm\u00fcller L. Multiple biochemical properties of the p53 molecule contribute to activation of polymerase iota-dependent DNA damage tolerance. Nucleic Acids Res. 2020;48:12188\u2013203.","journal-title":"Nucleic Acids Res"},{"key":"3377_CR58","doi-asserted-by":"publisher","unstructured":"Jansche R, Heitmeir B, Faust U, Pospiech H, Sutter C, Albig C et al. Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification. Cell Death Dis 2026;17. https:\/\/doi.org\/10.1038\/s41419-026-08463-0.","DOI":"10.1038\/s41419-026-08463-0"},{"key":"3377_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcdb.2020.07.004","volume":"113","author":"S Tye","year":"2021","unstructured":"Tye S, Ronson GE, Morris JR. A fork in the road: where homologous recombination and stalled replication fork protection part ways. Semin Cell Dev Biol. 2021;113:14\u201326.","journal-title":"Semin Cell Dev Biol"},{"key":"3377_CR60","doi-asserted-by":"publisher","first-page":"e66243","DOI":"10.1371\/journal.pone.0066243","volume":"8","author":"E Ribeiro","year":"2013","unstructured":"Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, et al. Triple negative breast cancers have a reduced expression of DNA repair genes. PLoS ONE. 2013;8:e66243.","journal-title":"PLoS ONE"},{"key":"3377_CR61","doi-asserted-by":"publisher","unstructured":"Liu W, Krishnamoorthy A, Zhao R, Cortez D. Two replication fork remodeling pathways generate nuclease substrates for distinct fork protection factors. Sci Adv 2020;6. https:\/\/doi.org\/10.1126\/sciadv.abc3598.","DOI":"10.1126\/sciadv.abc3598"},{"key":"3377_CR62","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1042\/BJ20102162","volume":"436","author":"EA Nam","year":"2011","unstructured":"Nam EA, Cortez D. ATR signalling: more than meeting at the fork. Biochem J. 2011;436:527\u201336.","journal-title":"Biochem J"},{"key":"3377_CR63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-biochem-062917-012415","volume":"87","author":"A Syed","year":"2018","unstructured":"Syed A, Tainer JA. The MRE11\u2013RAD50\u2013NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair. Annu Rev Biochem. 2018;87:263\u201394.","journal-title":"Annu Rev Biochem"},{"key":"3377_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1689-8","volume":"10","author":"LR Gomes","year":"2019","unstructured":"Gomes LR, Rocha CRR, Martins DJ, Fiore APZP, Kinker GS, Bruni-Cardoso A, et al. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. Cell Death Dis. 2019;10. 459.","journal-title":"Cell Death Dis"},{"key":"3377_CR65","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","volume":"59","author":"R Buisson","year":"2015","unstructured":"Buisson R, Boisvert JL, Benes CH, Zou L. Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase. Mol Cell. 2015;59:1011\u201324.","journal-title":"Mol Cell"},{"key":"3377_CR66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.molmed.2010.10.009","volume":"17","author":"CX Ma","year":"2011","unstructured":"Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2011;17:88\u201396.","journal-title":"Trends Mol Med"},{"key":"3377_CR67","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez Besteiro MA, Calzetta NL, Loureiro SM, Habif M, B\u00e9tous R, Pillaire M et al. Chk1 loss creates replication barriers that compromise cell survival independently of excess origin firing. EMBO J 2019;38. https:\/\/doi.org\/10.15252\/embj.2018101284.","DOI":"10.15252\/embj.2018101284"},{"key":"3377_CR68","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mrrev.2014.10.003","volume":"763","author":"MA Gonz\u00e1lez Besteiro","year":"2015","unstructured":"Gonz\u00e1lez Besteiro MA, Gottifredi V. The fork and the kinase: a DNA replication tale from a CHK1 perspective. Mutat Res Rev Mutat Res. 2015;763:168\u201380.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"3377_CR69","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1073\/pnas.1116345109","volume":"109","author":"J Speroni","year":"2012","unstructured":"Speroni J, Federico MB, Mansilla SF, Soria G, Gottifredi V. Kinase-independent function of checkpoint kinase 1 (Chk1) in the replication of damaged DNA. Proc Natl Acad Sci USA. 2012;109:7344\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3377_CR70","doi-asserted-by":"publisher","unstructured":"Jahjah T, Singh JK, Gottifredi V, Quinet A. Tolerating DNA damage by repriming: gap filling in the spotlight. DNA Repair (Amst) 2024; 142. https:\/\/doi.org\/10.1016\/j.dnarep.2024.103758.","DOI":"10.1016\/j.dnarep.2024.103758"},{"key":"3377_CR71","doi-asserted-by":"publisher","unstructured":"Ler AAL, Carty MP. DNA damage tolerance pathways in human cells: a potential therapeutic target. Front Oncol 2022;11. https:\/\/doi.org\/10.3389\/fonc.2021.822500.","DOI":"10.3389\/fonc.2021.822500"},{"key":"3377_CR72","doi-asserted-by":"publisher","unstructured":"Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett 2024;584. https:\/\/doi.org\/10.1016\/j.canlet.2024.216608.","DOI":"10.1016\/j.canlet.2024.216608"},{"key":"3377_CR73","doi-asserted-by":"crossref","unstructured":"Li J, Holzschu DL, Sugiyama T. PCNA is efficiently loaded on the DNA recombination intermediate to modulate polymerase \u03b4, \u03b7, and \u03b6 activities. Proc Natl Acad Sci USA 2013;110: 7672\u20137677.","DOI":"10.1073\/pnas.1222241110"},{"key":"3377_CR74","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/15384101.2022.2111769","volume":"22","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhou K, Xia X, Guo Y, Tao L. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells. Cell Cycle. 2023;22:200\u201312.","journal-title":"Cell Cycle"},{"key":"3377_CR75","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","volume":"84","author":"L Cadzow","year":"2024","unstructured":"Cadzow L, Brenneman J, Tobin E, Sullivan P, Nayak S, Ali JA, et al. The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination-deficient tumors. Cancer Res. 2024;84:3419\u201334.","journal-title":"Cancer Res"},{"key":"3377_CR76","doi-asserted-by":"publisher","first-page":"e11908","DOI":"10.15252\/emmm.201911908","volume":"12","author":"C Koch","year":"2020","unstructured":"Koch C, Kuske A, Joosse SA, Yigit G, Sflomos G, Thaler S, et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med. 2020;12:e11908.","journal-title":"EMBO Mol Med"},{"key":"3377_CR77","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0891-5849(89)90066-X","volume":"6","author":"OI Aruoma","year":"1989","unstructured":"Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6:593\u20137.","journal-title":"Free Radic Biol Med"},{"key":"3377_CR78","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559:279\u201384.","journal-title":"Nature"},{"key":"3377_CR79","doi-asserted-by":"publisher","unstructured":"Eberle J, Wiehe RS, Gole B, Mattis LJ, Palmer A, St\u00e4ndker L et al. A fibrinogen alpha fragment mitigates chemotherapy-induced MLL rearrangements. Front Oncol 2021; 11. https:\/\/doi.org\/10.3389\/fonc.2021.689063.","DOI":"10.3389\/fonc.2021.689063"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03377-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03377-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03377-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:01:26Z","timestamp":1791313286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03377-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3377"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03377-4","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and Consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"405"}}